Ingebjørg Baksaas

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

Richard B. Pollard, Jürgen K. Rockstroh, Giuseppe Pantaleo et al. · The Lancet Infectious Diseases · 2014 · 108 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Improvement of serum lipids and blood pressure during intervention with n‐3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia

Heidi Grundt, Dennis W Nilsen, Ø. Hetland et al. · Journal of Internal Medicine · 1995 · 63 citations

Life Sciences, Nutrition, Nutritional Sciences +17

National drug policies: the need for drug utilization studies

Ingebjørg Baksaas, P. K. M. Lunde · Trends in Pharmacological Sciences · 1986 · 62 citations

Pharmacy, Pharmaceutical Policy, Pharmacy Practice +14

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

Anne‐Marte Bakken Kran, Birger Sørensen, Jørgen Nyhus et al. · AIDS · 2004 · 49 citations

Life Sciences, Immunology, Infectious Diseases +17

Phase I Trial of a Therapeutic HIV Type 1 Vaccine, Vacc-4x, in HIV Type 1-Infected Individuals with or without Antiretroviral Therapy

Birgitta Åsjö, Helen Stavang, Birger Sørensen et al. · AIDS Research and Human Retroviruses · 2002 · 42 citations

Veterinary Medicine, Immunology, Infectious Diseases +17